144 related articles for article (PubMed ID: 12224477)
1. [Population screening for uterine cervix cancer: the negative effects of insufficient knowledge as to what is normal and abnormal].
van der Graaf Y
Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1569-71. PubMed ID: 12224477
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of population screening and rescreening for cervical cancer in the Netherlands.
Boon ME; de Graaff Guilloud JC
Acta Cytol; 1981; 25(5):539-42. PubMed ID: 6792845
[TBL] [Abstract][Full Text] [Related]
3. [Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996].
Bos AB; van Ballegooijen M; van den Akker-van Marle ME; Habbema JD
Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1586-90. PubMed ID: 12224483
[TBL] [Abstract][Full Text] [Related]
4. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
5. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
Nygård M; Daltveit AK; Thoresen SO; Nygård JF
BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
[TBL] [Abstract][Full Text] [Related]
6. [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening].
Berkers LM; van Ballegooijen M; van Kemenade FJ; Rebolj M; Essink-Bot ML; Helmerhorst TJ; Habbema JD
Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1288-94. PubMed ID: 17624160
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cervical cancer screening program at a rural community of South Africa.
Hoque M; Hoque E; Kader SB
East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
Koong SL; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
10. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
12. ["Cost-effectiveness" of cervical screening].
Kostova P
Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
[TBL] [Abstract][Full Text] [Related]
13. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
15. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
[TBL] [Abstract][Full Text] [Related]
17. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
[TBL] [Abstract][Full Text] [Related]
18. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women.
Yang B; Morrell S; Zuo Y; Roder D; Tracey E; Jelfs P
Cancer Causes Control; 2008 Aug; 19(6):569-76. PubMed ID: 18286380
[TBL] [Abstract][Full Text] [Related]
19. [Follow up after an abnormal pap smear: time interval acceptable, nature of follow up leaves room for improvement].
Geertsen M; Bais AG; Beerman H; Helmerhorst TJ
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2430-4. PubMed ID: 14694554
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
